Clinical trials located in

Sant Cugat del Vallès

Sant Cugat del Vallès city is located in Spain. Currently, 7 clinical trials are being conducted in this city.

Sant Cugat del Vallès, nestled in the shadow of the Collserola mountain range near Barcelona, Spain, boasts a rich tapestry of history and modernity. The city is renowned for its impressive Monastery of Sant Cugat, a stunning example of Catalan Romanesque architecture that dates back to the 9th century. This historical gem, with its remarkable cloister and intricate capitals, tells tales of medieval times. In contrast, Sant Cugat has evolved into a vibrant, affluent suburb, attracting professionals and families with its high quality of life, green spaces, and excellent educational institutions. The fusion of ancient heritage and contemporary lifestyle makes Sant Cugat del Vallès a unique blend of the past and present.

  • CT-EU-00023235

    Investigating efficacy and safety of new therapy in early-stage Parkinson’s disease

    This clinical trial aims to examine BIIB122, a new medication considered to potentially slow down the progression of early-stage Parkinson’s disease in patients aged between 30–80 years old. Participants will undergo treatment with either BIIB122 or a placebo equal in appearance but devoid of actual medicine. The trial’s routine includes a single daily medication intake for a timeframe between 48 and 144 weeks. To evaluate the medication’s efficacy, patients’ symptoms and their impact on everyday life will be observed using the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). In addition to this, safety assessment of BIIB122 will be a main focus of the study. The trial treats this as a double-blind study, anonymizing whether a patient takes the BIIB122 drug or a placebo.

    • BIIB122
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    • JNJ-81201887- new potential medication for Geographic Atrophy
    • Prednisone
    • Triamcinolone
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • New treatment study for Advanced Solid Cancers

    This study is about a new drug called AZD9574 which is being studied on people with advanced cancers, such as ovarian, breast, pancreatic, or prostate cancer. The trial aims to check how safe this drug is and how well it works, either alone or combined with other cancer drugs. Around 270 participants will be part of the study. The study will be divided into different parts. Some will focus on patients who have different types of cancer, while others will explore the effects of AZD9574 combined with other drugs. Doctors will track the patients’ health and how their bodies handle the drug. They will also collect data on the drug’s effectiveness and any side effects. Depending on the results, the trial might be expanded to include more participants or additional cancer types.

    • Datopotamab Deruxtecan/Dato-DXd
    • Trastuzumab deruxtecan/T-DXd
    • AZD9574- new potential medication for brain tumors
    • [11C]AZ1419 3391
    • Temozolomide
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Spain:

.